Extended Data Fig. 8: Plasma drug levels and CSF neurofilament light chain levels in patients with EIMFS.

a, b, Concentration of valeriasen in plasma after each administration in Patient 1 (a) and Patient 2 (b). c, d, Concentration of neurofilament light chain (NfL) in CSF prior to each administration in Patient 1 (c) and Patient 2 (d), as determined by Quanterix Simoa digital immunoassay. Shaded boxes indicate approximate interquartile reference ranges from healthy controls⁶⁰.